Amber Specialty Pharmacy announced that it will begin dispensing LIVTENCITY™ (maribavir), the first and only treatment indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet. LIVTENCITY™ is manufactured by Takeda.
Amber Specialty Pharmacy, a Hy-Vee, Inc. subsidiary, is a pioneer and leader in the specialty pharmacy industry with more than 23 years of experience providing specialized care for persons with chronic, complex medical conditions. Amber Specialty Pharmacy headquarters are located in Omaha, Nebraska, with an additional 20 locations throughout the United States and Puerto Rico.
The U.S. Food and Drug Administration approved Livtencity (maribavir) as the first drug for treating adults and pediatric patients (12 years of age and older and weighing at least 35 kilograms) with post-transplant cytomegalovirus (CMV) infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for CMV. Livtencity works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication.
CMV is a type of herpes virus that commonly causes infection in patients after a stem cell or organ transplant. CMV infection can lead to CMV disease and have a major negative impact on transplant recipients, including loss of the transplanted organ and death. Livtencity received Breakthrough Therapy and Priority Review designations for this indication.
Through this partnership, Amber Specialty Pharmacy’s best-in-class service model will support transplant facilities and patients throughout the country.
Their billing expertise and high-touch services garnered the attention and respect of the nation’s most prestigious transplant programs. Amber Specialty Pharmacy’s foundation in transplant care propelled them into other therapeutic categories, including Oncology and Rare and Orphan.
Takeaway: Amber Specialty Pharmacy was established in 1998 as the first specialty pharmacy to focus on the life-long health and needs of the transplant community